MarketCap
Facebook
X
Telegram
AnaptysBio Net Income | ANAB
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income AnaptysBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | -13.2 M | -145 M | -164 M | -129 M | -57.8 M | -19.9 M | -97.3 M | -61.7 M | -30.1 M | -4.26 M | -5.4 M | 3.53 M | -5.54 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 131 M | -164 M | -42.7 M |
Quarterly Net Income AnaptysBio
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -52.9 M | - | 15.1 M | -38.6 M | -39.3 M | - | -32.9 M | -46.7 M | -43.9 M | - | -37.3 M | -39.8 M | -44.3 M | - | -33.5 M | -32.6 M | -36.3 M | - | -6.67 M | -429 K | -18.2 M | - | -23.8 M | -21.5 M | -8.26 M | -20.3 M | -31 M | -24 M | -22.1 M | -17 M | -16 M | -13.6 M | -15.1 M | -6.86 M | -9.09 M | -2.68 M | -11.4 M | -4.58 M | -1.12 M | 2.32 M | -888 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.1 M | -52.9 M | -21 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cortexyme
CRTX
|
-84 M | - | -1.05 % | $ 67.1 M |  USA |
 |
Burford Capital Limited
BUR
|
62.6 M | $ 3.6 | -9.22 % | $ 789 M |  Britain |
 |
Daré Bioscience
DARE
|
-13.4 M | $ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
-136 M | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-19.4 M | $ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
317 M | $ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
457 M | $ 15.16 | 6.76 % | $ 13 B |  China |
 |
Aptorum Group Limited
APM
|
-1.36 M | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-33 M | $ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
-230 M | $ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-196 M | $ 0.05 | -14.81 % | $ 547 | USA |
 |
FSD Pharma
HUGE
|
-27 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
BioAtla
BCAB
|
-59.6 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
214 M | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-153 M | $ 24.77 | -3.73 % | $ 1.19 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
9.88 M | $ 13.47 | 4.1 % | $ 1.2 B | USA |
 |
ARCA biopharma
ABIO
|
-105 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-7.79 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-43.1 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-10.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
22.4 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-74.2 B | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
10.2 B | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-232 M | $ 0.36 | 0.59 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
-9.89 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-18.2 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
17.4 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-16.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
3 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-27 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-3.75 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-3.56 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-22.7 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
391 K | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-45.3 M | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
183 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
29.8 M | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
-27.1 M | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-117 M | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-210 M | - | - | $ 762 M |  Danmark |